GlassScriptPhysician profile
Jeffrey Einar Brink
NPI 1942206206
$8,657.25
in general payments reported to CMS, 2019-2025
25 companies · $819 in 2025
The $819 reported for 2025 was more than what 75% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,161 · 2020: $395 · 2021: $543 · 2022: $102 · 2023: $317 · 2024: $319 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $5,590.28 | 2019-2021 | |
| Stryker Corporation | $617.60 | 2019-2025 | Scopis Ent, Audion Et Dilation System |
| Acclarent, INC | $568.29 | 2019-2023 | Trudi Nav Cable, Acclarent Aera |
| Neurent Medical Limited | $368.34 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Inspire Medical Systems, INC. | $305.12 | 2023-2025 | Inspire |
| Ethicon US, LLC | $232.01 | 2020-2021 | |
| Alk-Abello, INC | $168.19 | 2019 | |
| Genzyme Corporation | $156.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $126.15 | 2025 | Nucala |
| Karl Storz Endoscopy-America | $90.00 | 2019 | |
| Genentech USA, INC. | $61.86 | 2019 | |
| Forte Bio-Pharma LLC | $52.25 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $49.85 | 2019 | |
| Intersect Ent, INC. | $45.75 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $35.09 | 2025 | Omidria |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.01 | 2025 | Keytruda |
| Smith+Nephew, INC. | $29.46 | 2020-2025 | |
| Hikma Pharmaceuticals USA | $21.31 | 2025 | Ryaltris |
| Phathom Pharmaceuticals, INC. | $17.93 | 2025 | Voquezna |
| Acelrx Pharmaceuticals, INC. | $17.92 | 2020 | |
| Aerin Medical INC. | $15.10 | 2022 | |
| Medtronic USA, INC. | $15.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.57 | 2021 | |
| Integra Lifesciences Corporation | $14.17 | 2025 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Pfizer INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Brink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.